The global epoetin market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market can be attributed to the increasing prevalence of anemia and kidney disorders in various regions across the globe. The North American region is expected to dominate the global epoetin market during the forecast period, followed by Europe and Asia Pacific. The global epoetin market has been segmented on the basis of type, application, and region. On the basis of type, it has been classified into erythropoietin alpha (Epoetialfa), erythropoietin beta (Epoetibeta), and darbepoietialfa). On the basis of application, it has been classified into anemia (cancer treatment) and kidney disorders (ESRD and dialysis). On the basis of region, it has been classified into North America, Latin America, Europe, Asia Pacific & Middle East & Africa. -The global Epoetin market is expected to grow at a CAGR of 5.2% during the forecast period, 2018-2025. -The global Epoetin market is expected to reach USD 2,814 million by 2025 from USD 1,907 million in 2018. -Increasing prevalence of anemia and chronic kidney disease are the major factors driving the growth of the global Epoetin market.
Industry Growth Insights published a new data on “Epoetin (Eritropoyetin) Market”. The research report is titled “Epoetin (Eritropoyetin) Market research by Types (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa), By Applications (Anemia (Cancer and HIV treatment), Kidney Disorders (ESRD and Dialysis), Others (Neural Disease and Wound healing)), By Players/Companies Amgen, Epoetin, Abcam, Johnson & Johnson, Hospira Inc, Roche, LG Life Sciences Ltd, Biocon, Intas Pharmaceuticals, Teva Pharmaceutical Industries Ltd, Ranbaxy Laboratories Ltd, Celltrion, Inc”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Epoetin (Eritropoyetin) Market Research Report
By Type
Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa
By Application
Anemia (Cancer and HIV treatment), Kidney Disorders (ESRD and Dialysis), Others (Neural Disease and Wound healing)
By Companies
Amgen, Epoetin, Abcam, Johnson & Johnson, Hospira Inc, Roche, LG Life Sciences Ltd, Biocon, Intas Pharmaceuticals, Teva Pharmaceutical Industries Ltd, Ranbaxy Laboratories Ltd, Celltrion, Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
238
Number of Tables & Figures
167
Customization Available
Yes, the report can be customized as per your need.
Global Epoetin (Eritropoyetin) Market Report Segments:
The global Epoetin (Eritropoyetin) market is segmented on the basis of:
Types
Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Anemia (Cancer and HIV treatment), Kidney Disorders (ESRD and Dialysis), Others (Neural Disease and Wound healing)
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amgen
- Epoetin
- Abcam
- Johnson & Johnson
- Hospira Inc
- Roche
- LG Life Sciences Ltd
- Biocon
- Intas Pharmaceuticals
- Teva Pharmaceutical Industries Ltd
- Ranbaxy Laboratories Ltd
- Celltrion, Inc
Highlights of The Epoetin (Eritropoyetin) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Epoetin-alfa
- Epoetin-beta
- Darbepoetin-alfa
- By Application:
- Anemia (Cancer and HIV treatment)
- Kidney Disorders (ESRD and Dialysis)
- Others (Neural Disease and Wound healing)
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Epoetin (Eritropoyetin) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Epoetin (Eritropoyetin) is a blood-thinning medication used to treat anemia. It works by helping the body produce more red blood cells.
Some of the major players in the epoetin (eritropoyetin) market are Amgen, Epoetin, Abcam, Johnson & Johnson, Hospira Inc, Roche, LG Life Sciences Ltd, Biocon, Intas Pharmaceuticals, Teva Pharmaceutical Industries Ltd, Ranbaxy Laboratories Ltd, Celltrion, Inc.
The epoetin (eritropoyetin) market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Epoetin (Eritropoyetin) Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Epoetin (Eritropoyetin) Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Epoetin (Eritropoyetin) Market - Supply Chain
4.5. Global Epoetin (Eritropoyetin) Market Forecast
4.5.1. Epoetin (Eritropoyetin) Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Epoetin (Eritropoyetin) Market Size (000 Units) and Y-o-Y Growth
4.5.3. Epoetin (Eritropoyetin) Market Absolute $ Opportunity
5. Global Epoetin (Eritropoyetin) Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Epoetin (Eritropoyetin) Market Size and Volume Forecast by Type
5.3.1. Epoetin-alfa
5.3.2. Epoetin-beta
5.3.3. Darbepoetin-alfa
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Epoetin (Eritropoyetin) Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Epoetin (Eritropoyetin) Market Size and Volume Forecast by Application
6.3.1. Anemia (Cancer and HIV treatment)
6.3.2. Kidney Disorders (ESRD and Dialysis)
6.3.3. Others (Neural Disease and Wound healing)
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Epoetin (Eritropoyetin) Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Epoetin (Eritropoyetin) Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Epoetin (Eritropoyetin) Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Epoetin (Eritropoyetin) Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Epoetin (Eritropoyetin) Demand Share Forecast, 2019-2029
9. North America Epoetin (Eritropoyetin) Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Epoetin (Eritropoyetin) Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Epoetin (Eritropoyetin) Market Size and Volume Forecast by Application
9.4.1. Anemia (Cancer and HIV treatment)
9.4.2. Kidney Disorders (ESRD and Dialysis)
9.4.3. Others (Neural Disease and Wound healing)
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Epoetin (Eritropoyetin) Market Size and Volume Forecast by Type
9.7.1. Epoetin-alfa
9.7.2. Epoetin-beta
9.7.3. Darbepoetin-alfa
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Epoetin (Eritropoyetin) Demand Share Forecast, 2019-2029
10. Latin America Epoetin (Eritropoyetin) Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Epoetin (Eritropoyetin) Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Epoetin (Eritropoyetin) Market Size and Volume Forecast by Application
10.4.1. Anemia (Cancer and HIV treatment)
10.4.2. Kidney Disorders (ESRD and Dialysis)
10.4.3. Others (Neural Disease and Wound healing)
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Epoetin (Eritropoyetin) Market Size and Volume Forecast by Type
10.7.1. Epoetin-alfa
10.7.2. Epoetin-beta
10.7.3. Darbepoetin-alfa
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Epoetin (Eritropoyetin) Demand Share Forecast, 2019-2029
11. Europe Epoetin (Eritropoyetin) Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Epoetin (Eritropoyetin) Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Epoetin (Eritropoyetin) Market Size and Volume Forecast by Application
11.4.1. Anemia (Cancer and HIV treatment)
11.4.2. Kidney Disorders (ESRD and Dialysis)
11.4.3. Others (Neural Disease and Wound healing)
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Epoetin (Eritropoyetin) Market Size and Volume Forecast by Type
11.7.1. Epoetin-alfa
11.7.2. Epoetin-beta
11.7.3. Darbepoetn-alfa
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Epoetin (Eritropoyetin) Demand Share, 2019-2029
12. Asia Pacific Epoetin (Eritropoyetin) Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Epoetin (Eritropoyetin) Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Epoetin (Eritropoyetin) Market Size and Volume Forecast by Application
12.4.1. Anemia (Cancer and HIV treatment)
12.4.2. Kidney Disorders (ESRD and Dialysis)
12.4.3. Others (Neural Disease and Wound healing)
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Epoetin (Eritropoyetin) Market Size and Volume Forecast by Type
12.7.1. Epoetin-alfa
12.7.2. Epoetin-beta
12.7.3. Darbepoetin-alfa
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Epoetin (Eritropoyetin) Demand Share, 2019-2029
13. Middle East & Africa Epoetin (Eritropoyetin) Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Epoetin (Eritropoyetin) Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Epoetin (Eritropoyetin) Market Size and Volume Forecast by Application
13.4.1. Anemia (Cancer and HIV treatment)
13.4.2. Kidney Disorders (ESRD and Dialysis)
13.4.3. Others (Neural Disease and Wound healing)
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Epoetin (Eritropoyetin) Market Size and Volume Forecast by Type
13.7.1. Epoetin-alfa
13.7.2. Epoetin-beta
13.7.3. Darbepoetin-alfa
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Epoetin (Eritropoyetin) Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Epoetin (Eritropoyetin) Market: Market Share Analysis
14.2. Epoetin (Eritropoyetin) Distributors and Customers
14.3. Epoetin (Eritropoyetin) Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Amgen
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Epoetin
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Abcam
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Johnson & Johnson
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Hospira Inc
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Roche
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. LG Life Sciences Ltd
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Biocon
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Intas Pharmaceuticals
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Teva Pharmaceutical Industries Ltd
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Ranbaxy Laboratories Ltd
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Celltrion, Inc
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook